
Alumis Inc (ALMS) Stock Forecast & Price Target
Alumis Inc (ALMS) Analyst Ratings
Bulls say
Alumis Inc presents a strong outlook due to its innovative approach in developing targeted therapies for autoimmune disorders, which is expected to significantly improve patient outcomes compared to traditional broad immunosuppression. The projected peak sales of $2 billion for its SLE product highlight the potential market impact, even when considering a conservative approval probability of only 20%. Additionally, the ongoing development of ESK-001 for psoriatic arthritis, supported by positive data from comparable therapies, further underscores the company’s potential for revenue growth in the autoimmune treatment space.
Bears say
The financial outlook for Alumis Inc is negatively impacted by several significant risks associated with its lead candidate ESK-001, including potential delays in advancing pivotal trials and demonstrating compelling efficacy for conditions such as psoriasis and systemic lupus erythematosus. Additionally, the company faces challenges in completing regulatory submissions and securing necessary approvals in key markets, which could hinder its ability to capitalize on market opportunities. The presence of broad competitive pressures in the immunology and inflammation sector, coupled with risks of slower-than-anticipated market uptake and possible dilution, further exacerbates the negative sentiment around the stock.
This aggregate rating is based on analysts' research of Alumis Inc and is not a guaranteed prediction by Public.com or investment advice.
Alumis Inc (ALMS) Analyst Forecast & Price Prediction
Start investing in Alumis Inc (ALMS)
Order type
Buy in
Order amount
Est. shares
0 shares